X4 Pharmaceuticals Inc XFOR.OQ XFOR.O is expected to show a rise in quarterly revenue when it reports results on May 1 for the period ending March 31 2025
The Boston Massachusetts-based company is expected to report revenue of $1.999 million, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for X4 Pharmaceuticals Inc is for a loss of $4.44 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for X4 Pharmaceuticals Inc is $67.50, above its last closing price of $5.34.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -5.40 | -5.25 | -6.00 | Missed | -14.3 |
Sep. 30 2024 | -4.50 | -5.19 | -5.40 | Missed | -4.1 |
Jun. 30 2024 | 3.80 | 0.17 | -2.10 | Missed | -1,325.9 |
Mar. 31 2024 | -4.65 | -4.89 | -7.80 | Missed | -59.6 |
Dec. 31 2023 | -5.10 | -4.59 | -3.00 | Beat | 34.6 |
Sep. 30 2023 | -4.61 | -4.47 | -0.30 | Beat | 93.3 |
Jun. 30 2023 | -4.86 | -4.90 | -9.90 | Missed | -102 |
Mar. 31 2023 | -6.35 | -6.51 | -4.80 | Beat | 26.3 |
This summary was machine generated April 29 at 13:16 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。